TROD Medical completes € 4.75M series B venture financing
Leuven, Belgium: 24 October 2013 - Medical device company TROD Medical nv/sa today announced that it has successfully completed a Series B financing round for € 4.75 million co-led by Vesalius Biocapital through its Vesalius Biocapital II Arkiv nv fund (Brussels, Belgium) and Capricorn Venture Partners through its Capricorn Health-tech Fund (Leuven, Belgium). Other investors in the Series B round are Gemma Frisius Fund, the spin-off fund of the University of Leuven (Leuven, Belgium) and the Flemish investment company PMV, through its healthcare fund FCI (Brussels, Belgium). This funding will be used to perform clinical studies in both Europe and the US to further validate the EncageTM technology for the focal treatment of prostate cancer.
As part of the financing, TROD Medical relocated its head office to Leuven, Belgium. In addition, TROD Medical will enter into a collaboration with the Medical Imaging Research Center (MIRC), an interdisciplinary research centre in the University Hospitals Leuven, campus Gasthuisberg.
More info on the press release.
Next > NGDATA becomes Oracle PartnerNetwork Gold Level Partner
Previous > CompactGTL and Avantium announce their collaboration